On November 1, 2018 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that two abstracts related to the company’s lead product candidate, tipifarnib, have been accepted for presentation at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, which will be held from December 1-4, 2018 in San Diego (Press release, Kura Oncology, NOV 1, 2018, View Source [SID1234530518]). The following abstracts were published today are now available on the ASH (Free ASH Whitepaper) website at www.hematology.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL) and CXCL12+ Peripheral T-cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study (Abstract # 2937)
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Poster II
Date: Sunday, December 2, 2018
Presentation Time: 6:00 p.m. – 8:00 p.m. PT
Location: San Diego Convention Center, Hall GH

Identification of Tipifarnib Sensitivity Biomarkers in T-cell Tumor Cell Lines (Abstract # 2851)
Session Name: 621. Lymphoma-Genetic / Epigenetic Biology: Poster II
Date: Sunday, December 2, 2018
Presentation Time: 6:00 p.m. – 8:00 p.m. PT
Location: San Diego Convention Center, Hall GH

Following presentation at the meeting, the posters will be available on Kura’s website at www.kuraoncology.com.